Nexell becomes free-standing company with Baxter support
This article was originally published in Clinica
Executive Summary
Nexell Therapeutics is set to become a free-standing cell therapy company as Baxter, which owns a minority share in Nexell, transfers sales and marketing rights back to Nexell, as well as committing financial support. At the same time, Nexell's parent company will fold itself into its subsidiary and adopt its name and corporate headquarters.